Mustang Bio (MBIO) to Offer Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Mustang Bio Announces Proposed Public Offering of Common Stock
June 10, 2020 4:01 PM EDTWORCESTER, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Mustang expects to grant the underwriters a 30day option to purchase up to an additional 15 percent of the shares of common stock offered in the public... More
